Kalk, N J
Guo, Q
Owen, D
Cherian, R
Erritzoe, D
Gilmour, A
Ribeiro, A S
McGonigle, J
Waldman, A
Matthews, P
Cavanagh, J
McInnes, I
Dar, K
Gunn, R
Rabiner, E A
Lingford-Hughes, A R
Article History
Received: 19 June 2016
Revised: 2 November 2016
Accepted: 13 November 2016
First Online: 10 January 2017
Competing interests
: NK was supported by a Wellcome Trust GlaxoSmithKline (GSK) Translational Medicine Training Fellowship to perform this research for her PhD and GSK supplied funds for the PET scans. JC is funded by the Wellcome Trust, Medical Research Council, the Chief Scientific Office of the Scottish Government and Pfizer. JC holds a recent Wellcome Trust award that involves collaboration with GSK, Lundbeck and Janssen & Janssen. ER is an employee of Imanova and an ex-GSK employee and GSK share holder. ER is a consultant for Opiant Pharma. PM was an employee of GSK while the study was being performed and owns stock in the company. Honoraria or educational grants have been paid to Imperial College for activities undertaken by PM for Biogen, Novartis, Roche, IXICO, Transparency Life Sciences and Adelphi Communications. PM receives research support from Biogen and GSK. AL-H has received research funding/support from Lundbeck and GSK, and honoraria for talks from Lundbeck. The remaining authors declare no conflict of interest.